The lipid mediator platelet-activating factor (PAF) plays a role in cancer. We investigated its presence in human colon carcinoma by assessing the levels of tissue phospholipase A 2 (PLA 2 , the key enzyme in the generation of the lyso-PAF precursor), lyso-PAF, PAF and acetylhydrolase activity (AHA, the key enzyme in PAF degradation) in colorectal cancer patients and by correlating them with Dukes' classification. The results highlighted that the tumour tissues of Dukes' A and B patients had significantly higher PLA 2 , lyso-PAF, PAF and AHA levels as compared with nontumour tissues. Dukes' C patients had higher PLA 2 , lyso-PAF and AHA levels but unchanged PAF. Dukes' D patients had higher AHA levels but unchanged PLA 2 , lyso-PAF and PAF. A pathophysiological role for PAF is suggested in human colon carcinoma. Oncogene (2003 Oncogene ( ) 22, 7222-7224. doi:10.1038 Keywords: acetylhydrolase activity; colorectal carcinoma; phospholipase A2; platelet-activating factor; receptor PAF (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a proinflammatory lipid molecule that sparks a wide range of immunoregulatory actions on numerous cells and organs (Denizot, 1997) . PAF derives from membrane precursors, 1-alkyl-2-acyl-glycero-3-phosphocholine. The action of a PLA 2 -dependent process generates the lyso-PAF precursor, and the subsequent acetylation of the lyso compound results in the PAF molecule. In turn, tissue PAF concentrations are downregulated by an AHA (Stafforini et al., 1996) . PAF acts through PAF receptors (PAF-R) present on the membrane of responsive cells (Izumi and Shimizu, 1995) . The PAF-R gene produces three different species of mRNA (i.e. transcript 1, transcript 2 and an elongated form of the transcript 2), which generate a unique membrane PAF-R (Youlyouz et al., 2002) . PAF is suspected to play a role in cancer since it stimulates the growth of several human tumour cell lines (Maggi et al., 1994; Bussolati et al., 2000) , enhances oncogene expression (Tripathi et al., 1991) , increases adhesiveness of tumour cells to vascular endothelia (Mannori et al., 2000) , and can contribute to tumour development by enhancing cell motility and by stimulating the angiogenic response (Montrucchio et al., 1998; Bussolati et al., 2000) . Recently, PAF was reported to inhibit proliferation, to induce differentiation and to suppress the malignant phenotype of human colon carcinoma cells (Wang and Chakrabarty, 2003) . In the present study, we investigated the putative involvement of PAF in human colon carcinoma by assessing the tissue levels of PAF and of its catabolic enzymes in colorectal tumours and correlated them with Dukes' classification of patients.
Investigation of 29 patients indicated that PLA 2 levels (the enzymatic activity that generated the lyso-PAF precursor) were dramatically elevated (P ¼ 0.0001, MannWhitney U-test) in the tumour tissue (1.570.2 U/mg) as compared with the adjacent tissue (0.670.06 U/mg). In agreement, amounts of the lyso PAF precursor were higher (P ¼ 0.0001) in the tumour tissue (2.770.4 ng/ mg) as compared with the adjacent tissue (0.970.1 ng/ mg). PAF levels were elevated (Po0.05) in the tumour tissue (12.174.3 pg/mg) as compared with the adjacent tissue (4.570.8 pg/mg). It is worth noting that AHA levels were markedly elevated (P ¼ 0.0001) in the tumour tissue (28.472.8 fmol/min/mg) as compared with the nontumour tissue (16.671.3 fmol/min/mg). Values for PLA 2 , lyso-PAF, PAF and AHA according to the Dukes' classification of patients are reported in Figure 1a -d, respectively. Data indicated that tumour tissues of Dukes' A and B patients had higher PLA 2 , lyso-PAF, PAF and AHA levels as compared with nontumour tissues. Dukes' C patients had higher PLA 2 , lyso-PAF and AHA levels but unchanged PAF. Dukes' D patients had higher AHA levels but unchanged PLA 2 , lyso-PAF and PAF. As reported in Figure 2b , reverse transcriptase-polymerase chain reaction (RT-PCR) experiments indicated that PAF-R transcript 2 were present in the tumour tissue and the adjacent tissue of colorectal cancer patients. PAF-R transcript 2 were detected in 16/16 patients (data not shown). PAF-R transcript 1 and the elongated form of the PAF-R transcript 2 were not detected (Figure 2a , b, respectively). Semiquantitative PCR experiments did not highlight the differences in the same patients for levels of PAF-R transcript 2 between tumour tissue and the adjacent tissue (data not shown).
This clinical study reports, for the first time, the presence of elevated amounts of PAF in colon carcinoma. Since PAF can generate biological responses detectable at levels as 10 fm, it is, thus, of evidence that regulating PAF levels is important since elevated levels of PAF might result in biological effects. Our results report that PAF and PAF-R transcripts are present in colon carcinoma. A higher PAF production is undoubtedly responsible for the elevated PAF amounts in colon carcinoma. Thus, increased PLA 2 levels are detected in tumour tissues as compared with nontumour ones. They lead to higher tumour concentrations of the lyso-PAF precursor that might be used to generate more PAF. In turn, tumour AHA levels are markedly elevated in order, most probably, to try to reduce PAFinduced proinflammatory events. Previous studies have demonstrated that PAF AHA abolishes the inflammatory effects of PAF on leucocytes and the vasculature Figure 1 PLA 2 (a), lyso PAF (b), PAF (c) and AHA (d) levels in tumour tissue and nontumour tissue of colorectal cancer patients according to the Dukes' classification. The procedure of the present study followed the rules edited by the French National Ethics. A total of 29 patients with a newly diagnosed and histological confirmed primary colorectal cancer were investigated (18 men and 11 women with a median age of 76 years). Tumour staging was performed according to the Dukes' and TNM classification. This classification is achieved by defining the characteristics of primary tumour (T), regional lymph node involvement (N) and metastasis (M). Among patients, six (20%) were Dukes' stage A (T1-2N0M0), 11 (37.7%) stage B (T3-4N0M0) and seven (25.7%) stage C (TxN1M0). Five (16.6%) patients with liver metastasis were classified as having Dukes' stage D (TxNxM1) disease. Specimens for the tumour and the tissue close to the tumour were obtained during the surgical procedure. Tissue samples were ethanol extracted (80% final), purified using thin-layer chromatography, and assayed for PAF activity by aggregation of washed rabbit platelets as previously reported (Dupuis et al., 1997) . Lyso PAF was measured in ethanolic extracts of biopsy samples after its chemical acetylation into PAF (Dupuis et al., 1997) . PLA 2 levels were assessed by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's recommendations (R&D Systems Europe, Ltd, Oxon, UK). AHA was determined by investigating degradation of 3 H-labelled PAF (Dupuis et al., 1997) . The hollow and solid bars represent normal and tumour tissues, respectively. The labels A-D at the bottom of each panel represent Duke staging. All the results are presented as mean7s.e.m. A paired Student's t-test was used to analyse intragroup differences. A P-value of o0.05 was considered significant. *Po0.05, **Po0.01 (Tjoelker et al., 1995) . The cellular origin of the tumourderived PAF remains speculative. However, a body of circumstantial evidences suggest the tumour as the source of these elevated PAF amounts. Thus, high levels of alky-acyl-glycerophosphocholine are reported in colon tumours (Dueck et al., 1996) and several carcinoma cell lines spontaneously secrete PLA 2 (Hendrickse et al., 1995; Kennedy et al., 1998) . The high levels of tumour-derived lyso-PAF subsequently released might be used to generate PAF. Reinforcing this hypothesis human colon mucosa and colon carcinoma cell lines produce PAF (Capasso et al., 1991; Fallani et al., 2002) . Despite that the intestinal mucosa is able to secrete AHA (Kald et al., 1996) , we may suggest that infiltrated macrophages are an appropriate candidate for the higher AHA tumour levels. Yet, infiltrated macrophages are reported in colorectal cancer tumours (Chaux et al., 1996; Shetye et al., 1998 ) and they are a major cell source of the PAF AHA (Stafforini et al., 1996) . We found that PAF levels of tumour tissues were higher than that of normal tissues in Dukes' A and B patients but not in Dukes' C and D ones. This result does not suggest that PAF may have a beneficial effect on tumour growth and metastasis, since tumour AHA levels are markedly elevated in both groups of patients. This enzymatic activity, which is reported to abolish the inflammatory effects of PAF on leucocytes and the vasculature (Tjoelker et al., 1995) , is generally considered as a local response for reducing PAFinduced proinflammatory events. Taken together, results of the present study suggest that PAF, which is present in the tumour, may have pathophysiological functions in the colon tumour tissues and might account, at least in part, for the neoangiogenic activity occurring in human colon cancer. The involvement of vascular endothelial growth factor (VEGF) in the vascularization of colon tumour is well known (Ellis et al., 2000; Ono and Miki, 2000) . In this context, PAF that can be produced by either cancer cells or inflammatory cells (Denizot, 1997) , and that it stimulates VEGF synthesis (Ko et al., 2002) and mediates VEGF action (Sirois and Edelman, 1997), might amplify local angiogenesis in colon tumours as previously suggested for breast ones (Montrucchio et al., 1998) .
